Evidence continues to grow that KRAS, once considered an "undruggable" target, 
can be targeted successfully in non-small cell lung cancer. In a phase I trial, 
the KRASG12C inhibitor sotorasib elicited responses in about a third of patients 
with the disease and was generally well tolerated.